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S334 Poster Session IIand mortality. In our institution, 734 patients received an UCBT
between 2000 and 2010. The focus of this study was 76 patients
(10.4%) who had primary (n 5 55) or secondary (n 5 21) GF. Pri-
mary GF was defined as failure to achieve an absolute neutrophil
count (ANC) $ 500/mcL for 3 consecutive by day +42 or chime-
rism \5% in all assessments after transplantation regardless of
ANC. Secondary GF was defined as loss of chimerism\5% after
having achieved 5% or more after UCBT, or ANC persistently be-
low 500/mcL after having achieved $ 500/mcL for 3 consecutive
days by day +42. Patients were grouped as those with malignant
disease/myeloablative conditioning (MA, n 5 28), malignant
disease/nonmyeloablative conditioning (NMA, n 5 26) and non-
malignant disease (non-Malig, n 5 22). The OS at 100 days for pa-
tients with primary GF was 49%(95%CI, 35-61%) and secondary
GF was 76%(95%CI, 52-89%) (p 5 0.03). Thirty-nine patients un-
derwent a second transplant at a median time of 50 days (range:
32-565). Excluding patients with slow primary engraftment (n 5
10), who were counted as primary GF, the remaining 27 patients
were considered too ill to withstand a second transplant. Second
transplant conditioning included: no additional conditioning (n 5
10), ATG/ALG 6 steroids (n 5 11), and chemotherapy 6
ATG/ALG (n 5 18). Cumulative incidence of engraftment after
2nd transplant was 77% at a median time of 16 days (range:
0-39). Engraftment was similar in all groups. After 2nd transplant,
OS was 69%(95%CI, 52-81%) at 100 days and 41%(95%CI,
26-56%) at 1 year. The day 100 survival was 32%(95%CI,
16-49%) for MA, 73%(95%CI, 52-86%) for NMA and
68%(95%CI, 45-83%) for non-Malig patients(p 5 0.01). In evalu-
ation of time to second transplant, the OS at 100 days was similar
for patients transplanted # 50 or . 50 days: (62%[95%CI,
38-79%] vs. 78% [95%CI, 51-91%] respectively, p 5 0.31); there
was also no difference in OS at 1 year (33%[95%CI, 15-53%] vs.
50%[95%CI, 26-70%] respectively, p 5 0.34). The most frequent
causes of death at day 100 after 2nd transplant were: second graft
failure, bacterial infection and disease recurrence. In conclusion,
patients with primary or secondary GF after UCBT who undergo
a second transplant have encouraging survival with over 40% sur-
viving 1 year, and identifying strategies to overcome graft failure
will help to improve upon this.Table 1. Demographic data of MDS patients underwent allo-
geneic HCT
N 5 79
Median Age at diagnosis, years (Range) 49.7 (19-65)
Median Age at transplant, years (Range) 51.0 (20-66)
Gender, M/F 43/36
IPSS#
High 17 (21.5%)
High Intermediate 40 (50.6%)
Low Intermediate 18 (22.8%)
Low 4 (5.1%)
Disease status at transplant
Complete remission 10 (12.7%)
Residual or active hematologic disease 69 (87.3%)
HCT-CI
0 22 (27.8%)
1-2 15 (20.0%)
$3 42 (52.2%)
HLA compatability
6/6 or 8/8 65 (72.3%)
4/6, 5/6 or 7/8 14 (27.7%)
Donor
Related 39 (49.4%)
Unrelated 40 (5.6%)
IPSS Cytogenetic classification
Favorable 26 (32.9%)
Intermediate 16 (20.2%)
Unfavorable* 37 (46.8%)
Monosomal karyotype 24 (30.4%)
#Internation Prognostic Scoring System.
*Unfavorable karyotypes include complex cytogenetic abnormality ($3
structural abnormalities) or abnormal chromosome 7.350
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Background: Surface expression of a4b7 integrin, a gut-homing
lymphocyte trafficking molecule, on peripheral blood memory T-
cells has been shown to be increased in patients who develop acute
intestinal graft-vs.-host disease (GVHD) after allogeneic hemato-
poietic cell transplantation (HCT).Decreased expression of a4b7 in-
tegrin on regulatory T-cells at engraftment has also been shown to
correlate with the development of intestinal GVHD. We hypothe-
sized that a4b7 integrin expressingmemory T-cells in the peripheral
blood at day +15 and day +30 after HCT would be associated with
the development of acute intestinal GVHD and survival outcomes.
Methods: Serial samples at day +15 and day +30 from 84 patients un-
dergoing either RIC or myeloablative conditioning allogeneic HCT
with peripheral blood stem cells were analyzed. Median follow-up
was 661 days (range 39, 907 days) among survivors. T-cell subsets
chosen for analysis included na€ıve and memory (defined by expres-
sion of CD45RA and CD45RO, respectively) CD4+ and CD8+ T-
cells. Expression of a4b7 integrin was assessed by flow cytometry.
Results: Increased percentage of memory CD4+ T-cells expressing
a4b7 integrin at day +15 correlated with increased non-relapse
mortality (NRM) (p 5 0.005) and decreased overall survival (OS)
(p 5 0.016). The cumulative incidence of NRM was 25% (21 /
84) (95% CI 16%, 34%) in this cohort. Expression on any na€ıve
T-cell subset, on memory CD8+ T-cells, or at day +30 was notshown to correlate with outcomes. Further analysis showed that
conditioning intensity, donor type, GVHD prophylaxis regimen,
use of in vivo T-cell depletion, and underlying disease had no sig-
nificant effect on the % of memory CD4+ T-cells expressing a4b7
integrin. Expression of a4b7 integrin on any T-cell subset did not
correlate with the development of acute intestinal GVHD, al-
though there were only 5 cases of grade II and 7 cases of grades
III-IV disease in this cohort.
Conclusion: Expression of a4b7 integrin on memory CD4+ T-cells
at day +15 after HCT predicts for NRM and OS. Analysis with
a larger number of samples is planned to confirm these results, but
continued study of a4b7 integrin as a biomarker or target of inter-
vention after HCT is warranted. This biomarker may be valuable
in identifying a high risk subset of patients who could benefit from
pre-emptive organ specific targeted intervention.
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Introduction: Monosomal karyotype (MK) is defined as the pres-
ence of two or more distinct autosomal monosomies or a single
monosomy associated with a structural abnormality. It was first de-
scribed as an adverse prognosis for acute myeloblastic leukemia. Re-
cently, Patnaik et al demonstrated adverse prognostic effect ofMK in
myelodysplastic syndromes (MDS). However, the effect of MK on
the allotransplant in MDS is not yet well described.
Methods: MDS patients who underwent allotransplant at the Uni-
versity of Iowa from 1990 to 2009 were retrospectively reviewed. Cy-
togenetic and patient’s data were abstracted from medical genetics
and transplant database. Patients were classified according to
